Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer Patients with untreated ES-SCLC were randomly assigned 1:1 ...
Stakeholders ask for flexibility, more examples in FDA guidance on overall survival in cancer trials
Stakeholders asked the US Food and Drug Administration for more examples in comments on a recently issued guidance on the use of overall survival as an endpoint in oncology drug clinical trials. They ...
The addition of pembrolizumab to neoadjuvant chemotherapy led to a significantly higher percentage of patients with early triple-negative breast cancer having a pathological complete response (defined ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results